We are hearing from a growing number of people with vitiligo who are still being told that dermatology services “can’t help” or that there is “no effective treatment available”. For vitiligo patients, referrals are being declined at triage stage, or patients are being advised not to pursue a dermatology appointment at all.

This is deeply concerning, and if you have been affected by this then we may be able to help.

Until recently, vitiligo was often treated very differently from other dermatological conditions. Many NHS dermatology departments historically did not routinely accept vitiligo referrals, largely because there was no licensed medicine specifically approved for its treatment. That position has now changed.

The NICE approval of ruxolitinib cream (Opzelura) for the treatment of non‑segmental vitiligo in people aged 12 and over is a significant moment. For the first time, there is a licensed, evidence‑based treatment option for vitiligo available within the NHS, alongside established second‑line options such as phototherapy.

This approval has the potential to transform vitiligo care, but only if people can actually access specialist assessment.

We fully recognise that NHS England is currently within a 90‑day implementation period, during which local services are working through pathways, funding arrangements and prescribing processes. So in reality some patients may be waiting until early June 2026 before they are able to receive a prescription. However, implementation periods are not a justification for refusing assessment altogether. At a minimum, people should now be able to:

We are still seeing patients being turned away at referral stage, sometimes using language that suggests vitiligo is untreatable, purely cosmetic, or outside the scope of NHS dermatology. This is outdated and, in some cases, incorrect.

To be clear, current approval applies to:

We know this last point is causing confusion.

Facial vitiligo can sometimes be subtle or early, and may only be clearly identified using a Wood’s lamp, a tool generally available in dermatology clinics, not primary care. As a result, some people are being told their vitiligo is not “significant enough” to warrant referral, even though specialist assessment is precisely what is required to determine this.

With consent, we are sharing redacted correspondence that illustrates exactly what many patients are experiencing.

In one recent case, a patient with long‑standing non‑segmental vitiligo, including facial involvement confirmed under Wood’s lamp, had their dermatology referral declined on the grounds that “no effective treatment is available” (Redacted letter above). After we supported the patient to challenge this decision (referencing current guidance and emerging treatment options) the dermatology service reviewed the case, acknowledged that the referral had been declined in error, and reinstated the appointment.

If you are based in the UK, and meet the above criteria for Ruxolitinib and are:

We want to hear from you. Your experiences will help us:

We can help you challenge the decision and access the treatment and support you are entitled to. Contact our team today: hello@vitiligosociety.org